
Opinion|Videos|November 25, 2024
Emerging data on oral selective estrogen receptor degraders
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating oral selective estrogen receptor degraders, including trials exploring use of elacestrant in combination with other therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5






























